The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 06, 2016

Filed:

Apr. 05, 2012
Applicants:

Maria Paz Ocaranza Jeraldino, Santiago, CL;

Jorge Emilio Jalil Milad, Santiago, CL;

Sergio Alejandro Lavandero González, Santiago, CL;

Mario Martin Chiong Lay, Santiago, CL;

Luis Fernando Michea Acevedo, Santiago, CL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/22 (2006.01); A61K 38/08 (2006.01); A61K 38/48 (2006.01); A61K 38/55 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/22 (2013.01); A61K 38/085 (2013.01); A61K 38/4813 (2013.01); A61K 38/553 (2013.01); A61K 38/556 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.


Find Patent Forward Citations

Loading…